DrugDevCovid19

Tracking the relevant researches of CADD drug development against COVID-19

Nicotinamide

ID MW HBD HBA
936  122.112
RB NOA Rings logP
131-0.37

Function

DrugBank ID:

DB02701


Description:

An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. [DrugBank]

Targets:

Exotoxin A (Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)); L-lactate dehydrogenase A chain (Humans); Poly [ADP-ribose] polymerase 1 (Humans); NAD-dependent protein deacylase sirtuin-5, mitochondrial (Humans); ADP-ribosyl cyclase 2 (Humans) [DrugBank]

Pharmacodynamics:

Not Available [DrugBank]

Structures

SMILES:

NC(=O)c1cccnc1

2D structures:  

3D structures:  

Docking in target protein

Receptor: Mpro

Docking Site: Catalytic pocket

Ligand: Nicotinamide

Vina score: -4.5

Off-target analysis based on ligand similarity (Homo sapiens)

Step 1 - Target prediction for Nicotinamide: SwissTargetPrediction

Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Nicotinamide in the SMILES input box.

Step 2 - Blind docking for Nicotinamide: CB-Dock

Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Nicotinamide to perform blind docking.